KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) Depreciation & Amortization - Total (2022 - 2025)

Pacific Biosciences Of California (PACB) has 4 years of Depreciation & Amortization - Total data on record, last reported at $2.7 million in Q4 2025.

  • For Q4 2025, Depreciation & Amortization - Total fell 3.73% year-over-year to $2.7 million; the TTM value through Dec 2025 reached $13.0 million, down 5.71%, while the annual FY2025 figure was $13.0 million, 5.71% down from the prior year.
  • Depreciation & Amortization - Total reached $2.7 million in Q4 2025 per PACB's latest filing, up from $2.5 million in the prior quarter.
  • Across five years, Depreciation & Amortization - Total topped out at $5.1 million in Q1 2025 and bottomed at $2.3 million in Q1 2022.
  • Average Depreciation & Amortization - Total over 4 years is $3.0 million, with a median of $2.8 million recorded in 2023.
  • The widest YoY moves for Depreciation & Amortization - Total: up 58.36% in 2025, down 41.31% in 2025.
  • A 4-year view of Depreciation & Amortization - Total shows it stood at $2.5 million in 2022, then grew by 17.03% to $3.0 million in 2023, then decreased by 4.5% to $2.8 million in 2024, then dropped by 3.73% to $2.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization - Total were $2.7 million in Q4 2025, $2.5 million in Q3 2025, and $2.7 million in Q2 2025.